About SOLU-KNEX®
Built on well-established ADC linker architectures, SOLU-KNEX® ADC linkers feature integrated solubilizing moieties, such as polyethylene glycol (PEG), amine-containing groups, or polysarcosine (PSAR), to dramatically enhance aqueous solubility. By carefully selecting and combining these groups, the linkers offer tunable physicochemical properties, reducing aggregation, improving stability, and enabling higher drug loading. This flexibility makes SOLU-KNEX® ADC linkers highly adaptable, supporting streamlined formulation, consistent manufacturing, and the development of next-generation ADCs with optimized efficacy and therapeutic performance.
Why Solubility Matters
Solubility is a critical determinant of ADC success because it directly impacts stability, safety, efficacy, and manufacturability throughout development and clinical use. Poorly soluble ADCs are prone to aggregation, which can reduce target binding, alter pharmacokinetics, increase immunogenicity, and raise the risk of off-target toxicity. Adequate solubility enables higher drug loading, more flexible formulation options, and consistent large-scale manufacturing, while supporting predictable biodistribution and controlled payload delivery in vivo. Optimizing solubility is essential to maximizing the therapeutic index and ensuring the developability of effective, reliable antibody–drug conjugates.
SOLU-KNEX® Advantages
Validated Core
SOLU-KNEX® ADC linkers are constructed on clinically validated linker chemistries, including MC-VC-PAB (maleimidocaproyl–valine–citrulline–p-aminobenzyl), leveraging their well-characterized in vivo stability and efficient intracellular payload release. These dipeptide-based linkers are designed to remain stable in systemic circulation while undergoing selective cleavage by lysosomal proteases such as cathepsin B upon internalization, enabling controlled and targeted drug release. By building on these established mechanisms, SOLU-KNEX® linkers retain the reliability of proven ADC platforms while providing a foundation for further optimization of conjugate performance.
Tunable Solubility
SOLU-KNEX® ADC linkers feature a tunable chemical architecture that enables precise modulation of hydrophobicity, polarity, and overall molecular composition. Through the controlled incorporation of hydrophilic elements, these linkers can be systematically optimized to enhance aqueous solubility across a broad range of payload classes and conjugation strategies. This design flexibility supports improved compatibility with structurally diverse cytotoxic agents, facilitates higher drug loading, and contributes to reduced aggregation and more robust formulation performance.
Broad Applications
SOLU-KNEX® ADC linkers are strategically designed to enable the next wave of targeted bioconjugate innovation, supporting emerging modalities such as dual-drug ADCs, antibody–oligonucleotide conjugates (AOCs), immune-stimulating antibody–drug conjugates (iADCs), degrader–antibody conjugates (DACs), and antibody–radionuclide conjugates (ARCs). Their modular and highly tunable architecture provides the flexibility to accommodate diverse payload classes, conjugation strategies, and complex linker–payload configurations. As bioconjugate design continues to evolve toward greater functional sophistication, SOLU-KNEX® offers a scalable and adaptable platform that empowers the development of multifunctional therapeutics with enhanced targeting precision, improved pharmacological profiles, and differentiated clinical potential.
SOLU-KNEX® is a registered trademark of Tenova Pharmaceuticals, Inc.